Acerus Pharmaceuticals Corporation trades with the ticker ASP on the TSX and is in the Drug Manufacturers – Specialty & Generic industry.
Overview
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men’s and women’s health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.
Looking to invest in Acerus Pharmaceuticals Corporation? Our analysis brings in the key facts, competitor research and valuation metrics for you to make an informed decision.
Table of Contents
show
ASP.TO Stock Price and Key Stats
ETF Key Stats
Exchange: TSX
Market Cap : $2.775MM
PE Ratio:
Price: 0.01 (Updated: 3/12/2024 0:47:16)
Acerus Pharmaceuticals Corporation (ASP) vs Competitors in Drug Manufacturers – Specialty & Generic
Lets see how ASP.TO stacks up against others in the Drug Manufacturers – Specialty & Generic asset management industry. We have identified its main peers as:Aleafia Health Inc, Aphria Inc, Correvio Pharma Corp, The Supreme Cannabis Company, Inc, Nuvo Pharmaceuticals Inc
.Drug Manufacturers – Specialty & Generic Industry Comparisons
| Company | Market Cap ($MM) | P/E Ratio | EV/EBITDA | Dividend Yield |
|---|---|---|---|---|
| Aleafia Health Inc (ALEF) | $189.563 | N/A | 0.0 | 0.0% |
| Aphria Inc (APHA) | $4,439.753 | N/A | 598.009 | 0.0% |
| Acerus Pharmaceuticals Corporation (ASP) | $2.775 | N/A | -2.796 | 0.0% |
| Correvio Pharma Corp (CORV) | $37.067 | N/A | 0.0 | 0.0% |
| The Supreme Cannabis Company, Inc (FIRE) | $255.583 | N/A | 0.0 | 0.0% |
EV/EBITDA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization – this ratio compares the value of a company, including debt, to the company’s cash earnings less non-cash expenses
Industry: companies that have a lot in common
Market Cap: Market Capitalization – the total value of all a corporation’s stock
N/A: Not Applicable or Not Available
P/E: Price-to-Earnings – this ratio relates a corporation’s share price to its earnings per share
Price: Stock Price – current value to buyers and sellers
Dividend Yield: Dividend or Distribution Yield
Comparisons within Drug Manufacturers – Specialty & Generic
- Acerus Pharmaceuticals Corporation (ASP) vs Aleafia Health Inc (ALEF)
- ALEF has higher EPS (-0.274 vs -4.41). ALEF has higher dividend yield (0.0% vs 0.0%). ALEF and ASP both have P/E’s under 0.
- Acerus Pharmaceuticals Corporation (ASP) vs Aphria Inc (APHA)
- APHA has higher EPS (0.116 vs -4.41). APHA has higher dividend yield (0.0% vs 0.0%). APHA and ASP both have P/E’s under 0.
- Acerus Pharmaceuticals Corporation (ASP) vs Correvio Pharma Corp (CORV)
- CORV has higher EPS (-0.879 vs -4.41). CORV has higher dividend yield (0.0% vs 0.0%). CORV and ASP both have P/E’s under 0.
- Acerus Pharmaceuticals Corporation (ASP) vs The Supreme Cannabis Company, Inc (FIRE)
- FIRE has higher EPS (-0.052 vs -4.41). FIRE has higher dividend yield (0.0% vs 0.0%). FIRE and ASP both have P/E’s under 0.
- Acerus Pharmaceuticals Corporation (ASP) vs Nuvo Pharmaceuticals Inc (NRI)
- NRI has higher EPS (0.024 vs -4.41). NRI has higher dividend yield (0.0% vs 0.0%). ASP has a P/E under 0, indicating NRI (P/E 2.6) is in a better position.
Our Recommendation: Hold
Features a lower EV/EBITDA ratio (-2.80) than the industry average (2.71), indicating attractive valuation.
How to Buy ASP stock on the TSX
You can buy on pretty much any online brokerage in Canada, since it trades on the TSX. If you are looking for some easy options take a look at these two:| Image | Product Title | Features | Price |
|---|---|---|---|
Editor's Choice  |
| Get $25 Signup Bonus | |
Reliable Pick  |
| Get $50 Free Stock Trades |
